Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CQCIH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD123A
|
|||||
| Synonyms |
SGN CD123A; SGNCD123A
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Acute myelogenous leukemia [ICD11:2B33]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD123 mAb h7G3ec
|
Antibody Info | ||||
| Antigen Name |
Interleukin-3 receptor subunit alpha (IL3RA)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB).
|
|||||
| Combination Type |
SGD-1910
|
|||||
| Puchem SID | ||||||
| TTD ID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.